Review: Combination therapy in high-risk stage II or stage III colon cancer: Current practice and future prospects

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 4, 2010, Pages 261-272

  Assed Bastos, Diogo ^a   Freitas, Daniela ^a   Coelho Ribeiro, Suilane ^b   Hoff, Paulo M ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

adjuvant chemotherapy; colon cancer; combined therapy; high risk stage II; stage III

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MONOCLONAL ANTIBODY; OXALIPLATIN; UFT;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 18Q; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; HAZARD RATIO; HUMAN; LOW DRUG DOSE; METASTASIS; MICROSATELLITE INSTABILITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW;

EID: 78649240521     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834010367905     Document Type: Review

References (59)

1. Ades, S. ( 2009) Adjuvant chemotherapy for colon cancer in the elderly: Moving from evidence to practice. Oncology ( Williston Park) 23: 162-167.
2. André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T. et al. (2004) Oxaliplatin, 5-fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351.
3. André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C. et al. (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 1-8.
4. André, T., Colin, P., Louvet, C., Gamelin, E., Bouche, O., Achille, E. et al. (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and II colon cancer: Results of a randomized trial. J Clin Oncol 21: 2896-2903.
5. Bertagnolli, M.M., Niedzwiecki, D., Comptom, C.C., Hahn, H.P., Hall, M., Damas, B. et al. (2009) Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and leukemia Group B protocol 89803. J Clin Oncol 27: 1814-1821.
6. Chang, G.J., Rodriguez-Bigas, M.A., Skibber, J.M. and Moyer, V.A. ( 2007) Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 99: 433-441.
7. de Dosso, S., Sessa, C. and Saletti, P. ( 2008) Adjuvant therapy for colon cancer: Present and perspectives. Cancer Treat Rev 35: 160-166.
8. de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C. et al. (2005) Oxaliplatin/5FU/ LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. ASCO Annual Meeting Proceedings. J Clin Oncol 23: 16S(abstract 3501).
9. de Gramont, A., Tournigand, C., André, T., Larsen, A.K. and Louvet, C. ( 2006) Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 33(6 Suppl 11): S42-S45.
10. Figueredo, A., Charette, M.L., Maroun, J., Brouwers, M.C. and Zuraw, L. ( 2004) Adjuvant therapy for stage II colon cancer: A systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22: 3395-3407.
11. Figueredo, A., Coombes, M.E. and Mukherjee, S. ( 2008) Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 16: CD005390.
12. Gill, G., Loprinzi, C.L., Sargent, D.J., Thomé, S.D., Alberts, S.R., Haller, D.G. et al. (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22: 1797-1806.
13. Goldberg, R.M., Tabah-Fisch, I., Bleiberg, H., de Gramont, A., Tournigand, C., Andre, T. et al. (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil / leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24: 4085-4091.
14. Gray, R., Barnwell, J., McConkey, C., Hills, R.K., Williams, N.S. and Kerr, D.J., QUASAR Collaborative Group (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370: 2020-2029.
15. Gryfe, R., Kim, H., Hsieh, E.T., Aronson, M.D., Holowaty, E.J., Bull, S.B. et al. (2000) Tumor microsatellite instability and clinical outcome in young patient with colorectal cancer. N Engl J Med 342: 69-77.
16. Haller, D.G., Catalano, P.J., Macdonald, J.S., O'Rourke, M.A., Frontiera, M.S., Jackson, D.V. et al. (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 23: 8671-8678.
17. Haller, D., Tabernero, J., Maroun, J., de Braud, F., Price, T., van Cutsem, E. et al. (2009) First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). Eur J Cancer Suppl 7: 4.
18. Hoff, P., Clarke, S., Cunningham, D., van Cutsem, E., Moore, M., Schmoll, H.J. et al. (2009) A three-arm phase III randomized trial of FOLFOX-4 vs. FOLFOX-4 plus bevacizumab vs. XELOX plus bevacizumab in the adjuvant treatment of patients with stage III or high-risk stage II colon cancer: Results of the interim safety analysis of the AVANT trial. Eur J Cancer Suppl 7: 324.
19. IMPACT B2; International Multicenter Pooled Analysis of B 2 Colon Cancer Trials Investigators. (1999) Efficacy of adjuvant fluorouracil and folinic acid in B 2 colon cancer. J Clin Oncol 17: 1356-1363.
20. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J. et al. (2009) Cancer statistics. CA Cancer J Clin 59: 225-249.
21. Kerr, D., Gray, R., Quirke, P., Watson, D., Yothers, G., Lavery, I.C. et al. (2009) A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 27(Suppl; abstract 4000): 15s.
22. Kim, G.P., Colangelo, L.H., Wieand, H.S., Paik, S., Kirsch, I.R., Wolmark, N. et al. (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25: 767-772.
23. Kopetz, S., Freitas, D., Calabrich, A.F. and Hoff, P.M. ( 2008) Adjuvant chemotherapy for stage II colon cancer. Oncology (Williston Park) 22: 260-270.
24. Kuebler, J.P., Wieand, H.S., O'Connell, M.J., Smith, R.E., Colangelo, L.H., Yothers, G. et al. (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25: 2198-2204.
25. Lanza, G., Gafà, R., Santini, A., Maestri, I., Guerzoni, L. and Cavazzini, L. ( 2006) Immunohistochemical test for MLH 1 and MSH 2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 24: 2359-2367.
26. Laurie, J.A., Moertel, C.G., Fleming, T.R., Wieand, H.S., Leigh, J.E., Rubin., J. et al. (1989) Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7: 1447-1456.
27. Le Voyer, T.E., Sigurdson, E.R., Hanlon, A.L., Mayer, R.J., Macdonald, J.S., Catalano, P.J. et al. (2003) Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21: 2912-2919.
28. Lembersky, B.C., Wieand, H.S., Petrelli, N.J., O'Connell, M.J., Colangelo, L.H., Smith, R.E. et al. (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24: 2059-2064.
29. Li, M.C. and Ross, S.T. ( 1976) Chemoprophylaxis for patients with colorectal cancer. Prospective study with five-year follow-up. JAMA 235: 2825-2828.
30. Locker, G.Y., Hamilton, S., Harris, J., Jessup, J.M., Kemeny, N., Macdonald, J.S. et al. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327.
31. Mamounas, E., Wieand, S., Wolmark, N., Bear, H.D., Atkins, J.N., Song, K. et al. (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17: 1349-1355.
32. Marshall, J.L., Haller, D.G., Gramont, A., Hochster, H.S., Lenz, H.J., Ajani, J.A. et al. (2007) Adjuvant therapy for stage II and III colon cancer: Consensus report of the International Society of Gastrointestinal oncology. Gastrointest Cancer Res 1: 146-154.
33. Moertel, C.G., Fleming, T.R., Macdonald, J.S., Haller, D.G., Laurie, J.A., Goodman, P.J. et al. (1990) Levamisole and fluouroracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358.
34. Moertel, C.G., Fleming, T.R., Macdonald, J.S., Haller, D.G., Laurie, J.A., Tangen, C.M. et al. (1995) Intergroup study of fluouroracil plus levamisole as adjuvant therapy for stage II/Dukes’ B 2 colon cancer. J Clin Oncol 13: 2936-2943.
35. O'Connell, M.J., Laurie, J.A., Kahn, M., Fitzgibbons, R.J., Erlichman, C., Sheperd, L. et al. (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: 295-300.
36. O'Connell, J.B., Maggard, M.A. and Ko, C.Y. ( 2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425.
37. Popat, S., Hubner, R. and Houlston, R.S. ( 2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609-618.
38. Poplin, E.A., Benedetti, J.K., Estes, N.C., Haller, D.G., Mayer, R.J., Goldberg, R.M. et al. (2005) Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23: 1819-1825.
39. Prandi, M., Lionetto, R., Bini, A., Francioni, G., Accarpio, G., Anfossi, A. et al. (2002) Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy. Results of a secondary analysis of a large scale adjuvant trial. Ann Surg 235: 458-463.
40. Quah, H.M., Chou, J.F., Gonen, M., Shia, J., Schrag, D., Landmann, R.G. et al. (2008) Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 51: 503-507.
41. QUASAR Collaborative Group (2000) Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial. Lancet 355: 1588-1596.
42. Ribic, C.M., Sargent, D.J., Moore, M.J., Thibodeau, S.N., French, A.J., Goldberg, R.M. et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257.
43. Saltz, L.B., Niedzwiecki, D., Hollis, D., Goldberg, R.M., Hantel, A., Thomas, J.P. et al. (2007) Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 25: 3456-3461.
44. Sargent, D.J., Goldberg, R.M., Jacobson, S.D., Macdonald, J.S., Labianca, R., Haller, D.G. et al. (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-1097.
45. Schmoll, H.J., Cartwright, T., Tabernero, J., Nowacki, M.P., Figer, A., Maroun, J. et al. (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. J Clin Oncol 25: 102-109.
46. Sinicrope, F.A. and Sargent, D.J. (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21: 369-373.
47. Smith, R.E., Colangelo, L., Wieand, H.S., Begovic, M. and Wolmark, N. ( 2004) Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 96: 1128-1132.
48. Sundararajan, V., Mitra, N., Jacobson, J.S., Grann, V.R., Heitjan, D.F. and Neugut, A.I. ( 2002) Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136: 349-357.
49. Takagawa, R., Fujii, S., Ohta, M., Nagano, Y., Kunisaki, C., Yamagishi, S. et al. (2008) Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol 15: 3433-3439.
50. Tejpar, T., Bosman, F., Delorenzi, M., Fiocca, R., Yan, P., Klingbiel, D. et al. (2009) Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60 / 00 trial). J Clin Oncol 27: 15s(Suppl; abstract 4001).
51. Twelves, C., Wong, A., Nowacki, M.P., Abt, M., Burris, III H., Carrato, A. et al. (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696-2704.
52. van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B. et al. (2009) Randomized phase III trial comparing biweekly infusional fluorouracil / leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27: 3117-3125.
53. Wolmark, N., Rockette, H., Fisher, B., Wickerman, D.L., Redmond, C., Fisher, E.R. et al. (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11: 1879-1887.
54. Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerman, D.L. et al. (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17: 3553-3559.
55. Wolmark, N., Rockette, H., Wickerham, D.L., Fisher, B., Redmond, C., Fisher, E.R. et al. (1990) Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic
56. infusion: Preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 8: 1466-1475.
57. Wolmark, N., Wieand, S., Kuebler, P.J., Colangelo, L., O'Connell, M.J., Yothers, G. et al. (2008) A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07. ASCO Annual Meeting Proceedings. J Clin Oncol 26: 15S(abstract 4005).
58. Wolmark, N., Yothers, G., O'Connell, M.J., Sharif, S., Atkins, J.N., Seay, T.E. et al. (2009) A phase III trial comparing mFOLFOX 6 to mFOLFOX 6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 27: 18s(Suppl; abstract LBA4).
59. Ychou, M., Raoul, J.L., Douillard, J.Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L. et al. (2009) A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20: 674-680.